W
WAVEMAN · COMPANY
PCRX · Pacira Biosciences, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

PCRX

Pacira BioSciences, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001396814
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$1.2M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
127
13F, latest reported quarter
REVENUE GROWTH
+3.6%
XBRL, annual
NET MARGIN
1.0%
CONVERSIONS · 180D
4
codes C/M, not in net · $411.2K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$1.2M over 180 days
-$214.3K over 90 days
below 62% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
127 funds added or opened last quarter
more than 74% of Pharma & Biotech
REVENUE
+3.6% year over year
more than 51% of Pharma & Biotech
MARGIN
1.0% net margin
more than 67% of Pharma & Biotech
BUYBACKS
$50.0M repurchased, FY to 2026-06-30
more than 56% of Pharma & Biotech
SHORT
18.1% of shares outstanding short · 13.4 days to cover · settled 2026-07-31
more than 94% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$1.2M across 5 people in 180 days.
127 funds added or opened positions in the latest 13F quarter, of 257 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -2.4%
-2.4%12M
-30%-19%-9%+1%2025-092025-102025-122026-032026-052026-072026-09 2025-12-09 · Cross Shawn sold $397.9K2026-04-23 · Cross Shawn sold $325.6K2026-02-02 · WILLIAMS KRISTEN sold $269.7K2025-11-10 · Cross Shawn sold $266.4K2025-12-10 · Cross Shawn sold $228.9K2026-06-04 · WILLIAMS KRISTEN sold $228.5K2026-04-20 · Cross Shawn sold $193.9K2026-06-11 · RIKER LAUREN sold $143.7K2025-11-17 · SLONIN JONATHAN sold $95.4K2026-02-02 · RIKER LAUREN sold $83.2K2026-03-17 · SLONIN JONATHAN sold $74.4K2026-04-21 · Cross Shawn sold $71.2K2026-08-17 · SLONIN JONATHAN sold $70.6K2025-09-04 · Ceesay Abraham sold $64.0K2026-04-22 · Cross Shawn sold $37.5K2026-01-05 · RIKER LAUREN sold $34.3K2026-03-17 · Froimson Mark sold $10.9K2026-08-17 · SLONIN JONATHAN filed to sell $70.6K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $1.2M sold by insiders over 180 days, 127 funds added last quarter, $70.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Pacira BioSciences, Inc. insiders sold a net $1.2M of stock across 142 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
SLONIN JONATHAN
Chief Medical Officer
SELL
2026-08-17
3,040.0
$70.6K
RIKER LAUREN
Senior Vice President, Finance
SELL
2026-06-11
6,115.0
$143.7K
WILLIAMS KRISTEN
Chief Administrative Officer
SELL
2026-06-04
10,259.0
$228.5K
Cross Shawn
Chief Financial Officer
SELL
2026-04-23
12,941.0
$325.6K
Cross Shawn
Chief Financial Officer
SELL
2026-04-22
1,500.0
$37.5K
142 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 137 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
6,705,809.0 sh
$170.1M
Doma Perpetual Capital Management LLC
2,777,794.0 sh
$70.5M
VANGUARD PORTFOLIO MANAGEMENT LLC
2,406,238.0 sh
$61.0M
DIMENSIONAL FUND ADVISORS LP
2,103,245.0 sh
$53.4M
STATE STREET CORP
2,059,977.0 sh
$52.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
SLONIN JONATHAN
FILED 2026-08-17
$70.6K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
ABSOLUTE FLEXIBLE FUND
$965.7K POSITION · AS OF 2026-03-31
3.0%
Easterly Snow Long/Short Opportunity Fund
$3.0M POSITION · AS OF 2026-02-28
2.8%
Impax Small Cap Fund
$17.0M POSITION · AS OF 2026-03-31
2.3%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$5.8M POSITION · AS OF 2026-03-31
1.9%
PROFUND VP PHARMACEUTICALS
$185.4K POSITION · AS OF 2026-03-31
1.8%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$192.6K POSITION · AS OF 2026-04-30
1.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · David Stack
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$6.9M
$4.2M
$1.5M
-26%
-9%
2022
$6.9M
$887.1K
$2.0M
-15%
-10%
2021
$6.9M
$5.5M
$2.1M
+33%
+40%
2020
$9.3M
$13.6M
$2.4M
+32%
+26%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$726.4M$701.0M$675.0M$666.8M
OPERATING INCOME$19.2M$-73.4M$87.7M$60.0M
NET INCOME$7.0M$-99.6M$42.0M$15.9M
EPS (DILUTED)0.16-2.150.890.34
OPERATING CASH FLOW$152.0M$189.4M$154.6M$145.3M
CASH$158.5M$276.8M$153.3M$104.1M
LONG-TERM DEBT$372.2M$383.5M$522.4M$689.5M
BUYBACKS$148.3M$25.0M$0$0
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →